ARWR
Arrowhead Research Corporation
stockNASDAQ
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 58.37 | 2026-10-14 | +0.86% | 4.384 |
| 1M | 68.79 | 2026-09-21 | -14.42% | 1.755 |
| 3M | 74.52 | 2026-07-21 | -21.00% | 1.618 |
| 6M | 71.05 | 2026-04-21 | -17.14% | 1.430 |
| 1Y | 38.03 | 2025-10-21 | +54.80% | 1.636 |
| 2Y | 20.49 | 2024-10-21 | +187.31% | — |
| 5Y | 66.89 | 2021-10-21 | -11.99% | 1.646 |
Arrowhead Research Corporation (NASDAQ:ARWR) stock price today is $58.87, and today's volume is 1,063,313. ARWR is down 0.085% today. The 30 day average volume is 2.32M. ARWR market cap is $8.32B with 141.25M shares outstanding.